Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?

2002 ◽  
Vol 10 (3) ◽  
pp. 177-180 ◽  
Author(s):  
Graeme N. Forrest ◽  
Stephen C. Schimpff ◽  
Alan Cross
Keyword(s):  
Febrile Neutropenia ◽  
Colony Stimulating Factors

Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005–2017

2020 ◽  
pp. 107815522091577 ◽  
Author(s):  
Jennifer R Schenfeld ◽  
Corina W Bennett ◽  
Shuling Li ◽  
Lucy J DeCosta ◽  
Renee R Jaramillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Febrile Neutropenia ◽  
Hodgkin Lymphoma ◽  
Colony Stimulating Factor ◽  
Myelosuppressive Chemotherapy ◽  
Colony Stimulating Factors ◽  
Non Hodgkin Lymphoma ◽  
Insured Patients ◽  
Stimulating Factor

Purpose Describe temporal changes in use of myelosuppressive chemotherapy, primary prophylactic colony-stimulating factor, and neutropenia-related hospitalization, in commercially insured patients. Methods Using a large commercial administrative database, we identified annual cohorts of adult patients diagnosed with breast or lung cancer, or non-Hodgkin lymphoma and initiating myelosuppressive chemotherapy during 2005–2017. We described yearly changes in proportions of myelosuppressive chemotherapy by febrile neutropenia risk category (high, intermediate, unclassified) and proportion of prophylactic colony-stimulating factor use and unadjusted incidence of neutropenia-related hospitalization in the first cycle of myelosuppressive chemotherapy. Results Annual cohorts included 4383–5888 eligible patients during 2005–2017. The proportion of eligible patients aged ≥ 65 years increased from 26.0% in 2005 to 58.2% in 2017. Myelosuppressive chemotherapy use with regimens with high risk for febrile neutropenia increased from 15.1% in 2005 to 31.0% in 2017; and regimens with intermediate risk for febrile neutropenia decreased from 63.7% to 48.1% in 2017. Prophylactic colony-stimulating factor use increased from 41.6% in 2005 to 54.3% in 2017. Crude incidence of neutropenia-related hospitalization for all cancers increased from 2.0% to 3.1%, with a substantial increase in neutropenia-related hospitalization observed among non-Hodgkin lymphoma patients (2.8% to 8.5%) during 2005–2017. Conclusion Among adult patients with breast and lung cancer, and non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of regimens with high risk for febrile neutropenia increased, as did the use of prophylactic colony-stimulating factors after 2005. Incidence of neutropenia-related hospitalization increased slightly, particularly among non-Hodgkin lymphoma patients. Further studies are required to understand this increasing trend of neutropenia-related hospitalization, changing patient-level risk factors, and febrile neutropenia management.

scholarly journals Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia

2018 ◽  
Vol 35 (11) ◽  
pp. 1816-1829 ◽  
Author(s):  
Paul Cornes ◽  
Pere Gascon ◽  
Stephen Chan ◽  
Khalid Hameed ◽  
Catherine R. Mitchell ◽  
...  
Keyword(s):  
Systematic Review ◽  
Febrile Neutropenia ◽  
Meta Analysis ◽  
Colony Stimulating Factors ◽  
Long Acting

scholarly journals Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

2013 ◽  
Vol 368 (12) ◽  
pp. 1131-1139 ◽  
Author(s):  
Charles L. Bennett ◽  
Benjamin Djulbegovic ◽  
LeAnn B. Norris ◽  
James O. Armitage
Keyword(s):  
Cancer Therapy ◽  
Febrile Neutropenia ◽  
Colony Stimulating Factors
Sign in / Sign up

Export Citation Format

Share Document